Mardia Samyoung Capillary Tubes Company Ltd vs Prism Medico Pharmacy Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Mardia Samyoung Capillary Tubes Company Ltd is ₹ 45.25 as of 23 Oct 15:30 . The P/E Ratio of Mardia Samyoung Capillary Tubes Company Ltd changed from 5.3 on March 2025 to 301.2 on March 2026 . This represents a CAGR of 653.86% over 2 yearsThe P/E Ratio of Prism Medico & Pharmacy Ltd changed from 47.6 on March 2026 to 47.6 on March 2026 . This represents a CAGR of 0.00% over 1 years The Market Cap of Mardia Samyoung Capillary Tubes Company Ltd changed from ₹ 1.32 crore on March 2021 to ₹ 673.4 crore on March 2026 . This represents a CAGR of 182.67% over 6 yearsThe Market Cap of Prism Medico & Pharmacy Ltd changed from ₹ 7.06 crore on March 2021 to ₹ 15.29 crore on March 2026 . This represents a CAGR of 13.75% over 6 years The revenue of Mardia Samyoung Capillary Tubes Company Ltd for the Jun '26 is ₹ 24.84 crore as compare to the Mar '26 revenue of ₹ 61.12 crore. This represent the decline of -59.36% The revenue of Prism Medico & Pharmacy Ltd for the Jun '26 is ₹ 0.09 crore as compare to the Mar '26 revenue of ₹ 0.28 crore. This represent the decline of -67.86% The ebitda of Mardia Samyoung Capillary Tubes Company Ltd for the Jun '26 is ₹ 1.42 crore as compare to the Mar '26 ebitda of ₹ 1.81 crore. This represent the decline of -21.55% The ebitda of Prism Medico & Pharmacy Ltd for the Jun '26 is ₹ -0.06 crore as compare to the Mar '26 ebitda of ₹ -0.12 crore. This represent the decline of -50% The net profit of Mardia Samyoung Capillary Tubes Company Ltd changed from ₹ -0.18 crore to ₹ 1.05 crore over 9 quarters. This represents a CAGR of NaN% The net profit of Prism Medico & Pharmacy Ltd changed from ₹ -0.09 crore to ₹ -0.06 crore over 9 quarters. This represents a CAGR of -16.49% The Dividend Payout of Mardia Samyoung Capillary Tubes Company Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Prism Medico & Pharmacy Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Mardia Samyoung Capillary Tubes Company Ltd

Mardia Samyoung Capillary Tubes Company Limited, a Joint Venture between Mardia Group Companies i.e., Mardia Extrusions & Mardia Tubes and Samyoung Jung Kwan Company of South Korea was incorporated in October, 1992.
Initially, the Company was engaged in manufacture of capillary and thin-walled pipes and tubes made from brass, stainless steel, copper and other copper alloys.
The foreign collaborator holds 25% stake in the Company.
At present, the Company is engaged in manufacture of non-ferrous metals. The foreign collaborator Samyoung, S.Korea has agreed to buy 6000 tpa of the finished products of the company apart from providing financial and technical collaboration.
The company's manufacturing facility with an installed capacity of 1800 tpa is located in Silvassa.

About Prism Medico & Pharmacy Ltd

Prism Medico and Pharmacy Limited was originally incorporated under the name of Woolite Mercantile Company Limited on 21st February, 1985.
The name of the Company was changed from Woolite Mercantile Company Limited to Prism Medico and Pharmacy Limited dated January 9, 2012.
Initially, the Company was engaged into Wholesale and Retail of straw, fodder and other animal/poultry feed.
It also engaged into investments, share trading, and financial activities. Over the past years, the Company was not able to carry out any major operations, resulting it engaged in trading. During FY 2022-23, the main objects of the Memorandum of Association of the Company were altered so as to manufacture, formulate, process, develop, refine, import, export, wholesale and/or retail trade all kinds of pharmaceuticals, antibiotics, drugs, medicines, biological, neutraceuticals, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines, chemicals, chemical products, dry salters, mineral waters, wines, cordials, liquors, soups, broths and other restoratives or foods and also to deal in medicinal goods.

FAQs for the comparison of Mardia Samyoung Capillary Tubes Company Ltd and Prism Medico & Pharmacy Ltd

Which company has a larger market capitalization, Mardia Samyoung Capillary Tubes Company Ltd or Prism Medico & Pharmacy Ltd?

Market cap of Mardia Samyoung Capillary Tubes Company Ltd is 359 Cr while Market cap of Prism Medico & Pharmacy Ltd is 42 Cr

What are the key factors driving the stock performance of Mardia Samyoung Capillary Tubes Company Ltd and Prism Medico & Pharmacy Ltd?

The stock performance of Mardia Samyoung Capillary Tubes Company Ltd and Prism Medico & Pharmacy Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mardia Samyoung Capillary Tubes Company Ltd and Prism Medico & Pharmacy Ltd?

As of October 25, 2026, the Mardia Samyoung Capillary Tubes Company Ltd stock price is INR ₹45.25. On the other hand, Prism Medico & Pharmacy Ltd stock price is INR ₹31.52.

How do dividend payouts of Mardia Samyoung Capillary Tubes Company Ltd and Prism Medico & Pharmacy Ltd compare?

To compare the dividend payouts of Mardia Samyoung Capillary Tubes Company Ltd and Prism Medico & Pharmacy Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.